Secondary Logo

Journal Logo

Institutional members access full text with Ovid®

Current and novel biomarkers in heart failure: bench to bedside

Ghashghaei, Roxana; Arbit, Boris; Maisel, Alan S.

Current Opinion in Cardiology: March 2016 - Volume 31 - Issue 2 - p 191–195
doi: 10.1097/HCO.0000000000000254
HEART FAILURE: Edited by Haissam Haddad
Buy
Editor's Choice

Purpose of review Natriuretic peptides, high-sensitivity cardiac troponins, and suppression of tumorigenicity 2 are novel biomarkers that reflect the intricate pathophysiology of heart failure and can thus be used for the diagnosis, management, and prognosis of heart failure.

Recent findings This review article describes the significance of B-type natriuretic peptide (BNP), N-terminal prohormone of BNP, ST2, and cardiac troponins. We outline their new roles in guiding the management of heart failure as well as strong prognostic indicators for adverse cardiovascular outcomes.

Summary By recognizing the diagnostic and prognostic significance of these biomarkers, clinicians can utilize these biomarkers to more accurately evaluate and risk stratify patients. These markers can also be used to help guide the medical management of heart failure. The best approach for an accurate diagnosis, management, and prognosis of heart failure will likely involve a multimarker panel of biomarkers, which may include high-sensitivity troponins, BNP, N-terminal prohormone of BNP, and ST2.

Department of Cardiology, University of California, San Diego, California, USA

Correspondence to Roxana Ghashghaei, Department of Cardiology, University of California, 200 West Arbor Drive, San Diego, CA 92103, USA. Tel: +1 949 331 6550; e-mail: rghashghaei@gmail.com

Copyright © 2016 Wolters Kluwer Health, Inc. All rights reserved.